Novo's Xultophy improves patient-reported outcomes

Novo Nordisk A/S (CDE:NVO; NYSE:NVO) said Xultophy insulin degludec/liraglutide improved patient-reported outcomes compared with Lantus insulin glargine in the Phase IIIb DUAL V trial to treat Type II diabetes in patients taking metformin. Xultophy is a fixed-dose combination of Novo's Victoza liraglutide, a long-acting analog of glucagon-like peptide-1 (GLP-1), and Tresiba insulin degludec, a long-acting insulin analog.

Patients receiving Xultophy had a significantly greater improvement in overall quality of life and treatment satisfaction compared with those receiving Lantus, as measured by total score on the Treatment Related Impact Measure for Diabetes (TRIM-D) questionnaire (p=0.003). The Xultophy group showed significant improvement in both treatment burden (p=0.017) and diabetes management (p<0.001). ...